| CAS ID: | 99210-65-8 |
| Molecular Formula: | |
| Molecular Weight: | g/mol |
| Monoisotopic Mass: | g/mol |
| Class: | Protein based biotech |
| Natural Product: | No |
| Other Names: | Peg-Intron | PEGINTERFERON ALFA-2B | PEGINTRON |
| Analysis: | N/A |
Trial Record 1
| ClinicalTrial ID | NCT01938781 | Disease | Liver fibrosis |
| Phase | Phase 4 | Status | Completed |
| First Received | September 10, 2013 | Last Verified | July 27, 2018 |
| Sponsor | Beijing Friendship Hospital | ||
Trial Record 2
| ClinicalTrial ID | NCT00148837 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Unknown |
| First Received | September 8, 2005 | Last Verified | February 8, 2008 |
| Sponsor | French National Agency for Research on AIDS and Viral Hepatitis | ||
Trial Record 3
| ClinicalTrial ID | NCT00049842 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | November 15, 2002 | Last Verified | April 4, 2017 |
| Sponsor | Merck Sharp & Dohme Corp. | ||
Trial Record 4
| ClinicalTrial ID | NCT00323804 | Disease | Liver fibrosis |
| Phase | Phase 2,Phase 3 | Status | Completed |
| First Received | May 10, 2006 | Last Verified | September 4, 2014 |
| Sponsor | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) | ||
Trial Record 5
| ClinicalTrial ID | NCT00252642 | Disease | Liver fibrosis |
| Phase | Not Applicable | Status | Completed |
| First Received | November 11, 2005 | Last Verified | March 20, 2017 |
| Sponsor | Virginia Commonwealth University | ||
Trial Record 6
| ClinicalTrial ID | NCT00122616 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | July 22, 2005 | Last Verified | February 22, 2012 |
| Sponsor | French National Agency for Research on AIDS and Viral Hepatitis | ||
Trial Record 7
| ClinicalTrial ID | NCT00686881 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Terminated |
| First Received | May 30, 2008 | Last Verified | April 6, 2017 |
| Sponsor | Merck Sharp & Dohme Corp. | ||
Trial Record 8
| ClinicalTrial ID | NCT00709059 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | July 3, 2008 | Last Verified | November 4, 2015 |
| Sponsor | Merck Sharp & Dohme Corp. | ||
Trial Record 9
| ClinicalTrial ID | NCT01463956 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | November 2, 2011 | Last Verified | January 24, 2017 |
| Sponsor | French National Agency for Research on AIDS and Viral Hepatitis | ||
Trial Record 10
| ClinicalTrial ID | NCT00301509 | Disease | Liver fibrosis |
| Phase | Phase 2,Phase 3 | Status | Completed |
| First Received | March 13, 2006 | Last Verified | March 13, 2006 |
| Sponsor | Casa Sollievo della Sofferenza IRCCS | ||
Trial Record 11
| ClinicalTrial ID | NCT00687219 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | May 30, 2008 | Last Verified | April 7, 2017 |
| Sponsor | Merck Sharp & Dohme Corp. | ||
Trial Record 12
| ClinicalTrial ID | NCT00811967 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Terminated |
| First Received | December 19, 2008 | Last Verified | March 13, 2017 |
| Sponsor | Merck Sharp & Dohme Corp. | ||
Trial Record 13
| ClinicalTrial ID | NCT00048724 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | November 8, 2002 | Last Verified | April 4, 2017 |
| Sponsor | Merck Sharp & Dohme Corp. | ||
| PubChem: | 47205818 |
| ChEMBL: | CHEMBL1201561 |